|
Characteristics
|
N = 56 (%)
|
|---|
|
Age
|
|
Median years (range)
|
72 (48–85)
|
|
Gender
|
|
Male/female
|
37 (66) / 19 (34)
|
|
Performance status
|
|
0 / 1 / 2
|
24(43) / 28 (50) / 4 (7)
|
|
Smoking status
|
|
Current / Former / Never
|
20(36) / 25(45) / 11 (20)
|
|
Histology
|
|
Adeno / Sq / Non-small
|
25(45) / 30(54) / 1(2)
|
|
Primary tumor location
|
|
Upper lobe or trachea / Middle or lower lobe
|
33(59) / 23 (41)
|
|
Clinical stage
|
|
|||A/|||B/|||C/Others
|
19(34) /14(25) /10(18) /13 (23)
|
|
PD-L1 Satus
|
|
≥ 50% /1–49% / < 1% / unknown
|
9(16) /11(20) / 19(24) / 17(30)
|
|
Irradiation technique
|
|
IMRT
|
28 (50)
|
|
3D-CRT
|
28 (50)
|
|
Total radiotherapy dose
|
|
60 Gy/30fr
|
48 (86)
|
|
66 Gy/33fr
|
5 (9)
|
|
54 Gy/27fr
|
1 (2)
|
|
50 Gy/25fr
|
2 (4)
|
|
Chemotherapy regimen
|
|
wCBDCA + PTX
|
26 (46)
|
|
CDDP + VNR
|
12 (21)
|
|
CDDP + Pemetrexed
|
12 (21)
|
|
CDDP + S-1
|
6 (11)
|
|
Pulmonary function test
|
|
Median %VC (range)
|
89.0 (53.5–124.4)
|
|
Median %FEV1.0 (range)
|
80.6 (46–126)
|
- Adeno adenocarcinoma, Sq squamous cell carcinoma, PD-L1 programmes cell death -ligand 1, IMRT intensity modulated radiation therapy, 3D-CRT three dimensional-conformal radiation therapy, fr fractions, w weeekly, CBDCA carboplatin, PTX paclitaxel, CDDP cisplatin, VNR vinorelbine, VC vital capacity, FEV forced expiratory volume
